ArticleFrontiers in neurology2011
Biomarkers in Alzheimer's disease.
Article in Frontiers in neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Progressive loss of independence in neuronal representations predicts cognitive decline.bioRxiv : the preprint server for biology · 2026Article
- Revolutionizing Alzheimer's Detection: Immune-Related Gene Biomarkers as Non-Invasive Predictors.Molecular neurobiology · 2025Article
- Neuronal Death and Biomolecular Condensates: Are There Any New Treatment Options for Alzheimer's Disease?Cells · 2025Review
- Article
- Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis.IBRO neuroscience reports · 2024Review
- Early MCI-to-AD Conversion Prediction Using Future Value Forecasting of Multimodal Features.Computational intelligence and neuroscience · 2021Article
- Amyloid imaging in Alzheimer's disease: a literature review.The journal of nutrition, health & aging · 2014Review
- Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease.PloS one · 2014Article
- A behavioral task predicts conversion to mild cognitive impairment and Alzheimer's disease.American journal of Alzheimer's disease and other dementias · 2013Article
- CSF biomarkers in different phenotypes of Parkinson disease.Journal of neural transmission (Vienna, Austria : 1996) · 2012Article
- The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in Psychiatry.Frontiers in neuroscience · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is the most common form of dementia in the elderly, and it is characterized by progressive impairment in multiple cognitive domains of sufficient severity to interfere with individuals' daily living activities. Historically, the diagnosis of AD has been based on the identification of a clinical syndrome, and accuracy studies of the current clinical criteria conducted in referral clinics have shown high sensitivity for AD. However, the identification of the disease is still not perfect, and there is growing evidence that the use of biomarkers will increase our ability to better indentify the underlying biology of AD, especially in its early stages. These biomarkers will improve the detection of the patients suitable for research studies and drug trials, and they will contribute to a better management of the disease in the clinical practice. In this review, we discuss the most studied biomarkers in AD: cerebrospinal fluid proteins, structural magnetic resonance imaging, functional neuroimaging techniques, and amyloid imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.